EP1071775A2 - Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre - Google Patents

Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre

Info

Publication number
EP1071775A2
EP1071775A2 EP99923403A EP99923403A EP1071775A2 EP 1071775 A2 EP1071775 A2 EP 1071775A2 EP 99923403 A EP99923403 A EP 99923403A EP 99923403 A EP99923403 A EP 99923403A EP 1071775 A2 EP1071775 A2 EP 1071775A2
Authority
EP
European Patent Office
Prior art keywords
undef
seq
prostate
frequency
gastrointestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99923403A
Other languages
German (de)
English (en)
Inventor
Thomas Specht
Bernd Hinzmann
Armin Schmitt
Christian Pilarsky
Edgar Dahl
André ROSENTHAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hinzmann Bernd Dr
PILARSKY, CHRISTIAN, DR.
ROSENTHAL, ANDRE, PROF.
SPECHT, THOMAS, DR.
Original Assignee
Metagen Gesellschaft fur Genomforschung Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagen Gesellschaft fur Genomforschung Mbh filed Critical Metagen Gesellschaft fur Genomforschung Mbh
Publication of EP1071775A2 publication Critical patent/EP1071775A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the invention relates to human nucleic acid sequences from endometrial tumor, which code for gene products or parts thereof, their functional genes, which code for at least one biologically active polypeptide, and their use.
  • the invention further relates to the polypeptides obtainable via the sequences and their use.
  • a cause of cancer death in women is the endometrial tumor, for which new therapies are necessary to combat it. Therapies used so far, such as Chemotherapy, hormone therapy or surgical removal of the tumor tissue often do not lead to complete healing.
  • the phenomenon of cancer is often associated with the over- or under-expression of certain genes in the degenerate cells, although it is still unclear whether these altered expression rates are the cause or the consequence of the malignant transformation. The identification of such genes would be an essential step in the development of new therapies for cancer.
  • ESTs Expressed Sequence Tags
  • cDNAs ie reverse-transcribed mRNAs
  • the EST sequences are determined for normal and degenerate tissues.
  • Various operators offer such databases commercially.
  • the ESTs in the LifeSeq database used here are typically between 150 and 350 nucleotides long. They represent an unmistakable pattern for a particular gene, although this gene is usually much longer (> 2000 nucleotides).
  • the nucleic acid sequences Seq are of particular interest. ID Nos. 1-126 and Seq. ID No 531-552, 554, 555.
  • the invention thus relates to nucleic acid sequences which encode a gene product or a part thereof, comprising a) a nucleic acid sequence selected from the group of the nucleic acid sequences Seq ID Nos. 1-126 and Seq. ID No 531-552, 554, 555.
  • nucleic acid sequences mentioned under a) or c) an allelic variation of the nucleic acid sequences mentioned under a) or c) a nucleic acid sequence which is complementary to the nucleic acid sequences mentioned under a) or b).
  • the invention further relates to a nucleic acid sequence according to one of the sequences Seq ID Nos 1-126 or a complementary or allelic variant thereof and the nucleic acid sequences thereof which have a 90% to 95% homology to a human nucleic acid sequence.
  • the invention also relates to the nucleic acid sequences Seq. ID No. 1 to Seq. ID No. 141 and Seq. ID No 531-552, 554, 555, which are expressed increased in the endometrial tumor.
  • the invention further relates to nucleic acid sequences comprising a part of the above-mentioned nucleic acid sequences, in such a sufficient size that they can be combined with the sequences Seq. ID Nos 1-126 and Seq. ID No 531-552, 554, 555 hybridize.
  • the nucleic acid sequences according to the invention generally have a length of at least 50 to 4500 bp, preferably a length of at least 150 to 4000 bp, in particular a length of 450 to 3500 bp.
  • expression cassettes can also be constructed in accordance with common process practice, with at least one of the inventive cassettes on the cassette
  • Nucleic acid sequences together with at least one generally known to the person skilled in the art known control or regulatory sequence, such as. B. a suitable promoter is combined.
  • the sequences according to the invention can be inserted in sense or antisense orientation.
  • a large number of expression cassettes or vectors and promoters are known in the literature which can be used.
  • Suitable control or regulatory sequence means suitable promoters.
  • Two preferred vectors are the pKK232-8 and the PCM7
  • promoters are specifically meant: lad, lacZ, T3, 11, gpt, lambda PR, trc, CMV, HSV thymidine kinase, SV40, LTRs from retrovirus and mouse
  • the DNA sequences on the expression cassette can encode a fusion protein which comprises a known protein and a biologically active polypeptide fragment.
  • the nucleic acid fragments according to the invention can be used to produce full-length genes.
  • the available genes are also the subject of the present invention.
  • the invention also relates to the use of the nucleic acid sequences according to the invention and the gene fragments obtainable from the use.
  • nucleic acid sequences according to the invention can be brought into host cells with suitable vectors, in which the heterologous part contains the genetic information contained on the nucleic acid fragments which is expressed.
  • Suitable host cells are e.g. B. prokaryotic cell systems such as E. coli or eukaryotic cell systems such as animal or human cells or yeasts.
  • nucleic acid sequences according to the invention can be used in sense or antisense form.
  • the invention further relates to the polypeptide sequences which have at least 80% homology, in particular 90% homology, to the polypeptide partial sequences of the ORF according to the invention.
  • the invention also relates to antibodies which are directed against a polypeptide or fragment thereof, which of the nucleic acids of the sequences Seq. ID No. 1 to Seq. ID 141 and Seq. ID No 531-552, 554, 555 can be encoded.
  • Antibodies are to be understood in particular as monoclonal antibodies.
  • the antibodies of the invention can include can be identified by a phage display method. These antibodies are also the subject of the invention.
  • the partial polypeptide sequences according to the invention can be used in a phage display method.
  • the polypeptides identified by this method which bind to the partial polypeptide sequences according to the invention are also the subject of the invention.
  • the nucleic acid sequences according to the invention can also be used in a phage display method.
  • polypeptides according to the invention of the sequences Seq. ID Nos. 142-528 and Seq. ID Nos. Seq. 561-575, 577-625, 630-635 can also be used as a tool for finding active substances against the endometrial tumor, which is also the subject of the present invention.
  • the present invention also relates to the use of the nucleic acid sequences according to the sequences Seq. ID No. 1 to Seq. ID No. 141 and Seq. ID No 531-552, 554, 555 for the expression of polypeptides which can be used as tools for finding active substances against the endometrial tumor.
  • the invention also relates to the use of the polypeptide partial sequences Seq found. ID No. 142-528 and Seq. ID Nos. Seq. 561-575, 577-625, 630- 635 as a drug in gene therapy for the treatment of the uterine tumor, or for the manufacture of a drug for the treatment of the uterine tumor.
  • the nucleic acid sequences according to the invention found can also be genomic or mRNA sequences.
  • the invention also relates to genomic genes, their exon and intron structure and their splice variants, obtainable from the cDNAs of the sequences Seq. ID No. 1 to Seq. ID No. 141 and Seq. ID No 531-552, 554, 555, and their use together with suitable regulatory elements, such as suitable promoters and / or enhancers.
  • genomic BAC, PAC and cosmid libraries are screened and specifically human clones are isolated via complementary base pairing (hybridization).
  • the BAC, PAC and cosmid clones isolated in this way are hybridized with the aid of fluorescence in situ hybridization to metaphase chromosomes and corresponding chromosome sections are identified on which the corresponding genomic genes lie.
  • BAC, PAC and cosmid clones are sequenced in order to elucidate the corresponding genomic genes in their complete structure (promoters, enhancers, silencers, exons and introns).
  • BAC, PAC and cosmid clones can be used as independent molecules for gene transfer (see FIG. 5).
  • the invention also relates to BAC, PAC and cosmid clones containing functional genes and their chromosomal localization, according to the sequences Seq. ID. No. 1 to Seq. ID No. 141 and Seq. ID No 531-552, 554, 555, for use as a vehicle for gene transfer.
  • nucleic acids nucleic acids are to be understood in the full invention: mRNA, partial cDNA, full length cDNA and genomic genes (chromosomes).
  • N either nucleotide A, T, G or C
  • Fig. 1 shows the systematic gene search in the Incyte LifeSeq database.
  • Fig. 2a shows the principle of EST assembly.
  • Fig. 2b1-2b4 shows the entire principle of EST assembly.
  • Fig. 3 shows in silico subtraction of gene expression in different tissues
  • 4a shows the determination of the tissue-specific expression via electronic Northern.
  • Fig. 4b shows the electronic Northern
  • Fig. 5 shows the isolation of genomic BAC and PAC clones.
  • a partial DNA sequence S e.g. B. a single EST or a contig of ESTs are using a standard program for homology search, z. B. BLAST (Altschul, SF, Gish W., Miller, W., Myers, EW and Lipman, DJ (1990) J. Mol. Bioi, 215, 403-410), BLAST2 (Altschul, SF, Madden, T. L, Schaffer, AA, Zhang, J., Zhang, Z., Miller, W. and Lipman, DJ (1997) Nucleic Acids
  • tissue-ordered (private or public) EST libraries certainly.
  • FASTA Pearson, WR and Lipman, DJ (1988) Proc. Natl. Acad. Sci. USA 85 2444-2448
  • the (relative or absolute) tissue-specific occurrence frequencies of this partial sequence S determined in this way are referred to as electronic Northern blot.
  • Musculoskeletal system 0.0034 0.0180 0.19045.2530
  • Musculoskeletal system 0.0154 0.0120 1.28500.7782

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des séquences d'acide nucléique humaines (ARNm, ADNc, séquences génomiques) provenant d'une tumeur de l'endomètre, qui codent pour des produits géniques ou pour des parties desdits produits géniques, ainsi que leur utilisation. Elle concerne également les polypeptides codés par lesdites séquences et leur utilisation.
EP99923403A 1998-04-17 1999-04-15 Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre Withdrawn EP1071775A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19817948 1998-04-17
DE19817948A DE19817948A1 (de) 1998-04-17 1998-04-17 Menschliche Nukleinsäuresequenzen aus Endometrium-Tumor
PCT/DE1999/001174 WO1999054461A2 (fr) 1998-04-17 1999-04-15 Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre

Publications (1)

Publication Number Publication Date
EP1071775A2 true EP1071775A2 (fr) 2001-01-31

Family

ID=7865426

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99923403A Withdrawn EP1071775A2 (fr) 1998-04-17 1999-04-15 Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre

Country Status (5)

Country Link
US (1) US6620923B1 (fr)
EP (1) EP1071775A2 (fr)
JP (1) JP2002532055A (fr)
DE (1) DE19817948A1 (fr)
WO (1) WO1999054461A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030003507A1 (en) 1999-06-02 2003-01-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7014996B1 (en) 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
NZ512052A (en) 1998-12-01 2003-10-31 Sumitomo Pharma Novel tumor antigen protein art-1 and tumor antigen peptide thereof
WO2000043513A1 (fr) * 1999-01-21 2000-07-27 Millennium Pharmaceuticals, Inc. Recepteur 17723 couple a la proteine g
HUP0202930A2 (en) * 1999-03-26 2002-12-28 Smithkline Beecham Biolog Novel compounds
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
ES2272309T3 (es) 1999-08-03 2007-05-01 Millennium Pharmaceuticals, Inc. 15571, una nueva molecula de tipo gpcr de la familia de tipo secretina y sus usos.
JP2003517297A (ja) * 1999-09-23 2003-05-27 ライジェル・ファーマシューティカルズ・インコーポレイテッド チェックポイント遺伝子関連細胞周期タンパク質、組成物および使用法
FR2800388A1 (fr) * 1999-10-29 2001-05-04 Pf Medicament Clonage, expression et caracterisation d'un gene exprime dans des cellules tumorales et implique dans la regulation de la reponse immune
ES2171104B1 (es) * 1999-11-29 2003-12-16 Univ Oviedo Procedimiento de identificacion de la metaloproteasa humana matrilisina-2.
FR2802945A1 (fr) * 1999-12-28 2001-06-29 Pf Medicament Nouvelle metalloprotease matricielle mmp-25 homologue de la matrilysine
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001249317A1 (en) * 2000-03-21 2001-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
AU2001263342A1 (en) * 2000-05-19 2001-12-03 Millennium Pharmaceuticals, Inc. 32263, a putative human biotin transcarboxylase and uses thereof
AU2001260309A1 (en) * 2000-05-19 2001-12-03 F.Hoffmann-La Roche Ag A process for determining the tumoricidal potential of a sample by the use of a nucleic acid which is downregulated in human tumor cells
WO2001098543A2 (fr) * 2000-06-21 2001-12-27 Diadexus, Inc. Procede de diagnostic, de controle, de stadification, d'imagerie et de traitement du cancer du sein
WO2002012329A2 (fr) * 2000-08-03 2002-02-14 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer de la tete et du cou
CA2420840A1 (fr) * 2000-09-01 2003-02-27 Epigenomics Ag Procede de determination du degre de methylation de cytosines determinees d'adn genomique dans le contexte sequentiel 5'-cpg-3'
AU2002253104A1 (en) * 2001-03-07 2002-09-19 Galapagos Genomics B.V. Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds
US20030211039A1 (en) * 2001-05-29 2003-11-13 Macina Roberto A. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
EP1408333A3 (fr) * 2001-10-03 2006-10-25 Pfizer Products Inc. Diagnostic et traitement de la maladie d'Alzheimer
JP2007525195A (ja) * 2003-06-02 2007-09-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド ヒト慢性リンパ球性白血病に関連する細胞表面タンパク質
CN101384727A (zh) * 2005-12-31 2009-03-11 健泰科生物技术公司 磷酸化的cop1分子及其用途
DK2546365T3 (en) 2008-09-03 2017-01-16 Univ Johns Hopkins Genetic changes of isocitrate dehydrogenase and other genes in malignant glioma
US20110229480A1 (en) * 2008-09-04 2011-09-22 Oxford Biotherapeutics Ltd Pta072 protein
WO2011119595A1 (fr) * 2010-03-22 2011-09-29 Auburn University Constructions de phages, séquences et compositions d'antigènes pour immunocontraception d'animaux
EP4110467A4 (fr) * 2020-03-31 2024-03-27 The Administrators of the Tulane Educational Fund Peptides antiviraux à large spectre
WO2022172264A1 (fr) * 2021-02-11 2022-08-18 Ramot At Tel Aviv University Ltd. Compositions et méthodes de traitement d'une maladie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2248136A1 (fr) * 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Facteur i, ii et iii de liaison de steroides specifique a l'endometre humain
US6174992B1 (en) * 1997-03-21 2001-01-16 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor I, II and III

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9954461A3 *

Also Published As

Publication number Publication date
WO1999054461A2 (fr) 1999-10-28
DE19817948A1 (de) 1999-10-21
US6620923B1 (en) 2003-09-16
JP2002532055A (ja) 2002-10-02
WO1999054461A3 (fr) 2000-07-06

Similar Documents

Publication Publication Date Title
WO1999054461A2 (fr) Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre
AU2020203837B2 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
US6262333B1 (en) Human genes and gene expression products
KR102239125B1 (ko) 인간 이디오타입을 갖는 설치류 항체를 인코딩하는 폴리뉴클레오티드 및 이를 포함하는 동물
KR102630357B1 (ko) 단백질 발현이 어려운 다중-부위 ssi 세포
KR20210049859A (ko) 게놈을 조절하는 방법 및 조성물
AU2016376191A1 (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
AU2016364667A1 (en) Materials and methods for treatment of Alpha-1 antitrypsin deficiency
WO1995014772A1 (fr) Signature genique
KR20150091058A (ko) Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
EP1073727A2 (fr) Sequences d'acide nucleique humain provenant de tissu de tumeur ovarienne
WO1999055858A2 (fr) Sequences nucleotidiques humaines obtenues a partir d'un tissu tumoral du pancreas
KR20080096495A (ko) 소과 동물에서 배최장근 최대력, 근내 지방, 식용우소매유통 생산량 및 순 사료 섭취량으로부터 선택된 형질을평가하는 방법
KR20190104400A (ko) 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
US20020065394A1 (en) Secreted proteins and polynucleotides encoding them
WO1999054460A2 (fr) Sequences d'acide nucleique provenant du tissu normal de la vessie
EP1070125A2 (fr) Sequences d'acides nucleiques humains provenant de tissus mammaires sains
AU2017336160A1 (en) Screening methods using olfactory receptors and novel compounds identified using the same
KR101978399B1 (ko) 자궁내막증에 대한 진단 마커로서의 돌연변이 유전자 및 이의 용도
CN113249470A (zh) 用于肺癌的体外诊断或预后的方法
KR102477906B1 (ko) 유도만능 줄기세포 분화 특이적 lncRNA, 및 이의 용도
KR20110110030A (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
JP2002017375A (ja) 全長ｃＤＮＡ合成用プライマー、およびその用途
KR20120106721A (ko) 신경발생 및 이의 조절에 관련된 유전자, 방법, 그리고 조성물
KR102364720B1 (ko) 교모세포종 진단용 바이오마커 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001019

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: METAGEN PHARMACEUTICALS GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PILARSKY, CHRISTIAN, DR.

Owner name: SPECHT, THOMAS, DR.

Owner name: ROSENTHAL, ANDRE, PROF.

Owner name: HINZMANN, BERND, DR.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041103